Investigational drug · Phase 3
Ficlatuzumab
Also called: AV-299
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
14
Any phase or sponsor naming "Ficlatuzumab"
First trial start
2024
Jan 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ficlatuzumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ficlatuzumab" as an intervention, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
AVEO Pharmaceuticals, Inc.Industry
NCT06064877 · 410 participants (planned) · Start Jan 11, 2024 · Primary completion Aug 2027
Drug: Ficlatuzumab; Cetuximab · For: Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Gilbert, Arizona; Tucson, Arizona; Los Angeles, California · 112 sites in all
- A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerPivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT01039948 · 203 participants · Start Dec 2009 · Primary completion Aug 2013
Drug: AV-299 + gefitinib; Gefitinib · For: Carcinoma, Non-Small Cell-Lung; Lung Neoplasms; Lung Cancer and 1 more
Sites: Shatin N.T., Hong Kong; Kuala Lumpur, Malaysia; Kuala Pahang, Malaysia · 26 sites in all
University of ArizonaAcademic, hospital or other
NCT03422536 · 78 participants · Start Dec 5, 2017 · Primary completion Mar 29, 2022
Drug: Cetuximab; Ficlatuzumab · For: Head and Neck Basaloid Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma and 21 more
Sites: Tucson, Arizona; New Haven, Connecticut; Tampa, Florida · 6 sites in all
AVEO Pharmaceuticals, Inc.Industry
NCT00725634 · 41 participants · Start Sep 2008 · Primary completion Dec 2010
Drug: AV-299; AV-299 + erlotinib · For: Malignant Solid Tumor; Lymphomas; Multiple Myeloma
Sites: Scottsdale, Arizona; Columbus, Ohio; San Antonio, Texas
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03316599 · 26 participants · Start Jan 17, 2018 · Primary completion Oct 10, 2020
Drug: Gemcitabine; Nab-paclitaxel and 1 more · For: Pancreatic Cancer
Sites: Boston, Massachusetts · 2 sites in all
AVEO Pharmaceuticals, Inc.Industry
NCT00969410 · 19 participants · Start Aug 2009 · Primary completion Mar 2011
Drug: AV-299 · For: Malignant Solid Tumour; Liver Metastases
Sites: Barcelona, Spain
C. Babis AndreadisAcademic, hospital or other
NCT02109627 · 17 participants · Start May 1, 2015 · Primary completion Dec 2, 2019
Drug: Ficlatuzumab; Cytarabine · For: Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Sites: San Francisco, California
- Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Completed
James J LeeAcademic, hospital or other
NCT02277197 · 14 participants · Start Aug 2015 · Primary completion Jun 2016
Drug: Ficlatuzumab; Cetuximab · For: Carcinoma, Squamous Cell of Head and Neck; Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma, Head And Neck
Sites: Pittsburgh, Pennsylvania · 3 sites in all
AVEO Pharmaceuticals, Inc.Industry
NCT02318368 · 10 participants · Start Nov 2014 · Primary completion Jan 2017
Drug: Ficlatuzumab; Erlotinib and 1 more · For: Non-small Cell Lung Cancer
Sites: Fresno, California; Redondo Beach, California; Boca Raton, Florida · 47 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
Bauman JE, Saba NF, Roe D, et al. · J Clin Oncol 2023
- Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis.
Wang C, Wang L, Li Q, et al. · World Neurosurg 2023
- Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
Perez K, Chiarella AM, Cleary JM, et al. · Oncologist 2023
- Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang VE, Blaser BW, Patel RK, et al. · Blood Cancer Discov 2021
- Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB, Brodrick P · Drugs 2021
- A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.
Panahi Y, Mohammadzadeh AH, Behnam B, et al. · Adv Exp Med Biol 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.